Telix Pharmaceuticals completed patient enrollment for its Phase 3 registration study of Illuccix in Japan. The study evaluates the efficacy and safety of 68Ga-PSMA-11 PET/CT imaging in Japanese patients with biochemically recurrent prostate cancer. This milestone supports the company's strategy to gain regulatory approval in a major global nuclear medicine market.
In a concurrent development, Telix opened a first-of-its-kind radiopharmaceutical facility in Melbourne, Australia. This multi-million dollar site integrates research, manufacturing, and patient administration capabilities. The facility strengthens Australia’s sovereign manufacturing for precision cancer care and accelerates the clinical translation of new treatments.